Short answer · Medically reviewed summary · Last updated: 2026-05-08
Dysferlinopathy, which includes Miyoshi Myopathy, is a rare genetic disorder with an estimated global prevalence of approximately 1 to 9 per 1,000,000 individuals. While exact figures remain uncertain due to frequent underdiagnosis, this condition is considered an ultra-rare muscle disease that affects both males and females equally across all ethnic groups. What is the estimated prevalence of Dysferlinopathy - Miyoshi Myopathy? Determining the precise prevalence of Dysferlinopathy - Miyoshi Myopathy is challenging because the clinical presentation varies widely, often leading to misdiagnosis as other forms of muscular dystrophy.
What is the prevalence of Dysferlinopathy - Miyoshi Myopathy?
Prevalence of Dysferlinopathy - Miyoshi Myopathy: how many people are affected worldwide, differences by sex and region, with sources.
Dysferlinopathy, which includes Miyoshi Myopathy, is a rare genetic disorder with an estimated global prevalence of approximately 1 to 9 per 1,000,000 individuals. While exact figures remain uncertain due to frequent underdiagnosis, this condition is considered an ultra-rare muscle disease that affects both males and females equally across all ethnic groups.
What is the estimated prevalence of Dysferlinopathy - Miyoshi Myopathy?
Determining the precise prevalence of Dysferlinopathy - Miyoshi Myopathy is challenging because the clinical presentation varies widely, often leading to misdiagnosis as other forms of muscular dystrophy. According to Orphanet, the estimated prevalence is roughly 1 in 200,000, though this varies by region. Within the DiseaseMaps.org community, we have 33 individuals who have shared their experiences with Dysferlinopathy - Miyoshi Myopathy, providing a unique, real-world perspective that highlights the diagnostic journey many patients face before receiving an accurate diagnosis.
What is the typical age of onset and gender distribution?
Dysferlinopathy - Miyoshi Myopathy is primarily an adult-onset condition, though symptoms can appear in late adolescence. The age of onset typically ranges from 15 to 30 years old. There is no known gender bias in the incidence of Dysferlinopathy - Miyoshi Myopathy; both males and females are affected with equal frequency, as the condition is inherited in an autosomal recessive pattern.
Why is accurate data on Dysferlinopathy - Miyoshi Myopathy limited?
Accurate epidemiological data for Dysferlinopathy - Miyoshi Myopathy is difficult to capture for several key reasons:
- Diagnostic Delays: Patients often undergo years of testing before identifying the DYSF gene mutation.
- Phenotypic Variability: The disease can manifest as either limb-girdle muscular dystrophy type R2 or Miyoshi Myopathy, confusing early clinical classification.
- Lack of Registries: Because it is an ultra-rare condition, centralized global registries are still evolving.
Next steps
- Consult a neuromuscular specialist or a clinical geneticist to confirm a diagnosis through genetic testing.
- Join the DiseaseMaps.org community to connect with other patients and share experiences.
- Monitor clinical trial databases like ClinicalTrials.gov for research regarding Dysferlinopathy - Miyoshi Myopathy.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
References
- Orphanet: Dysferlinopathy (ORPHA:254)
- NIH Genetic and Rare Diseases (GARD) Information Center: Dysferlinopathy
- OMIM (Online Mendelian Inheritance in Man): #254130 (Miyoshi Myopathy)
- The Jain Foundation: Expert resources on Dysferlin-related muscular dystrophy
